Improvement of the inhibitory effect of xanthones on NO production by encapsulation in PLGA nanocapsules

Journal of Drug Targeting

Volumn 13, Issue 2, 2005, Pages 129-135

  Teixeira, Maribel ^a,b   Ceroqueira, Fátima ^a   Barbosa, Carlos Maurício ^a,c   Nascimento, Maria São José ^a   Pinto, Madalena ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b Inst Superior Cien da Saude Norte   (Portugal)

^c CETMED   (Portugal)

Author keywords

3 methoxycanthone; F774 macrophages; Nanocapsules; Nitric oxide; PLGA; Xanthone

Indexed keywords

3 METHOXYXANTHONE; GAMMA INTERFERON; NANOCAPSULE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHATIDYLCHOLINE; POLYGLACTIN; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG FORMULATION; DRUG MIXTURE; DRUG STRUCTURE; ENCAPSULATION; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; HUMAN; IN VITRO STUDY; METABOLIC INHIBITION; PHAGOCYTOSIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; CELL LINE; CELL SURVIVAL; DRUG CARRIERS; LACTIC ACID; MACROPHAGES; MICE; NANOSTRUCTURES; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRITES; NITROPRUSSIDE; PHAGOCYTOSIS; POLYGLYCOLIC ACID; POLYMERS; XANTHONES;

EID: 17444407527     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860400027717     Document Type: Article

References (32)

1. Aramaki Y. 2000. Liposomes as immunomodulator-inhibitory effect of liposomes on NO production from macrophages. Biol Pharm Bull 23:1267-1274.
2. Aramaki Y, Nitta F, Matsuno R, Morimura Y, Tsuchiya S. 1996. Inhibitory effects of negatively charged liposomes on nitric oxide production from macrophages stimulated by LPS. Biochem Biophys Res Commun 220:1-6.
3. De las Heras B, Navarro A, Godoy A, Villar AM. 1997. Inhibition of the induction of nitric oxide synthase in J774 macrophages by andalusol, a diterpenoid from Sideritis foetens clem. Pharm Pharmacol Lett 7:111-112.
4. Fernandes EGR, Silva AMS, Cavaleiro JAS, Silva FM, Borges MF, Pinto MMM. 1995. Hepatoprotective activity of xanthones and xanthonolignoids against tert-butylhydroperoxide-induced toxicity in isolated rat hepatocytes comparison with silybin. Pharm Res 12:1756-1760.
5. 13C Spectroscopy of mono-, di-, tri- and tetrasubstituted xanthones. Magn Reson Chem 36:305-309.
6. García D, Delgado R, Ubeira FM, Leiro J. 2002. Modulation of rat macrophage function by the Mangifera indica L extracts Vimang and mangiferin. Int Immunopharmacol 2:707-806.
7. Gonzalez MJ, Nascimento MSJ, Cidade H, Pinto MM, Kijjoa A, Anantachoke C, Silva AMS, Herz W. 1999. Immunomodulatory activity of xanthones from Calophyllum teysmannii var. inuphylloide. Planta Méd 65:368-371.
8. Green BN, Warguer DA, Glowgoski J, Skipper PL, Wishnok JS, Tannenbaum JR. 1982. Analysis of nitrate, nitrite and (15) N nitrate in biological fluids. Anal Biochem 126:131-138.
9. Gross SS, Wollin MS. 1995. Nitric oxide: Pathophysiological mechanisms. Ann Rev Physiol 57:737-769.
10. Jain R, Shah NH, Malick AW, Rhodes C. 1998. Controlled drug delivery by biodegradable poly(ester) devices: Different preparative approaches. Drug Dev Ind Pharm 24:703-727.
11. Kolb H, Kolb-Bachofen V. 1992. Nitric oxide: A pathogenic factor in autoimmunity. Immunol Today 13:157-159.
12. Kuo PC, Schoeder RA. 1995. The emerging multifaceted roles of nitric oxide. Ann Surg 221:220-235.
13. Leiro JM, Álvarez E, Arranz JA, Siso IG, Orallo F. 2003. In vitro effects of mangiferin on superoxide concentrations and expression of the inducible nitric oxide synthase, tumour necrosis factor-α and transforming growth factor-β genes. Biochem Pharmacol 65:1361-1371.
14. Lin CN, Chung MI, Liou SJ, Lee TH, Wang JP. 1996. Synthesis and anti-inflammatory effects of xanthone derivatives. J Pharm Pharmacol 48:532-538.
15. Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, Russell SW, Murphy WJ. 1993. Macrophage nitric oxide synthase gene: Two upstream regions mediate induction by interferon g and lipopolysaccharide. Proc Natl Acad Sci USA 90:9730-9734.
16. Maaßen S, Fattal F, Müller RH, Couvreur P. 1993. Cell cultures for the assessment of toxicity and uptake of polymeric particulate drug carriers. STP Pharma Sci 3:11-22.
17. Morin C, Barrat G, Fessi H, Devissaguet J-P, Puisieux F. 1994. Improved intracellular delivery of muramyl dipeptide analog by means of nanocapsules. Int J Immunopharmacol 16:451-456.
18. Mosqueira VC, Legrand P, Gulik A, Bourdon O, Gref R, Labarre D, Barratt G. 2001. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 22:2967-2979.
19. Mossman T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
20. Pedro M, Cerqueira F, Sousa ME, Nascimento MSJ, Pinto M. 2002. Xanthones as inhibitors of growth of human cancer cell lines and their effects on the proliferation of human lymphocytes in vitro. Bioorg Med Chem 10:3725-3730.
21. Peres V, Nagem TJ, de Oliveira FF. 2000. Tetraoxygenated naturally occurring xanthones. Phytochemistry 55:683-710.
22. Pinto M, Nascimento MSJ. 1997. Anticomplementary activity of hydroxy- and methoxyxanthones. Pharm Pharmacol Lett 7:125-127.
23. Pinto MMM, Sousa EP. 2003. Natural and synthetic xanthonolignoids: Chemistry and biological activities. Current Med Chemistry 10:1-12.
24. Saraiva L, Fresco P, Pinto E, Kijjoa A, Gonzalez MJ, Gonçalves J. 2002a. Differential activation of protein kinase C isoforms by euxanthone, revealed by an in vivo yeast phenotypic assay. Planta Med 68:1039-1041.
25. Saraiva L, Fresco P, Pinto E, Sousa E, Pinto M, Gonçalves J. 2002b. Synthesis and in vivo modulatory activity of protein kinase C of xanthone derivatives. Bioorg Med Chem 10:3219-3227.
26. Saraiva L, Fresco P, Pinto E, Sousa E, Pinto M, Gonçalves J. 2003. Inhibition of α, βI, δ and ζ protein kinase C isoforms by xanthonolignoids. J Enzyme Inhib Med Chem 18:357-370.
27. Seyler I, Appel M, Devissaguet J-P, Legrand P, Barratt G. 1999. Macrophage activation by a lipophilic derivative of muramyl-dipeptide within nanocapsules: Investigation of the mechanism of drug delivery. J Nanopart Res 1:91-97.
28. Tabata Y, Ihada Y. 1988. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. J Biomed Mater Res 22:837-858.
29. Teixeira M, Afonso CMM, Pinto MMM, Barbosa CM. 2003. A validated HPLC method for assay of xanthone and 3-methoxyxanthone in PLGA nanocapsules. J Chromatogr Sci 41:371-376.
30. Teixeira M, Alonso MJ, Pinto MMM, Barbosa CM. 2004. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. Eur J Pharm Biopharm (accepted for publication).
31. Thull U, Kneubuhler S, Testa B, Borges MFM, Pinto MM. 1993. Substituted xanthones as selective and reversible monoamine oxidase A (MAO-A) inhibitors. Pharm Res 10:1187-1190.
32. Wang J, Zhang Q. 2001. Uptake of cyclosporine A loaded colloidal drug carriers by mouse peritoneal macrophages in vitro. Acta Pharmacol Sin 22:57-61.